Neoplasms, Glandular and Epithelial

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma

Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Vorasidenib Expanded Access Program

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Intended Use Study of the BD SurePath Plus™ Pap

Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin

Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

HR Versus RFA for HCC in Patients With PHT

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer